November 30th, 2015| Thousands of young male patients have been diagnosed with Gynecomastia as a result of using the antipsychotic drug, Risperdal®. The condition is identified by the development of excess breast tissue in young men and often requires surgery to correct. Since Risperdal and Gynecomastia has been linked, thousands of victims have filed lawsuits against the maker of the drug, Johnson & Johnson. One of those cases recently came to a close, with a jury awarding a large sum of damages to the victim. According to FiercePharma, Johnson & Johnson was ordered to pay $1.75 million in damages to a man who developed Gynecomastia as a result of using the company’s product. Court documents showed the company was aware of the risks their product posed to users as early as 2001, yet the company took no corrective action until years later. This isn’t the first Risperdal drug injury case to come to a conclusion. In 2013, Johnson & Johnson agreed to pay $2.2 billion to settle claims that the company had used off-label marketing techniques to sell the medication. The company has also established a multi-million trust to cover expenses related to future lawsuits involving the drug. At Berg Injury Lawyers, we’ve seen first-hand the serious harm that can be caused by certain prescription medications. That’s why the California drug injury lawyers applaud the decisions that have been reached recently regarding Risperdal and hope these ruling can bring closure to the matter for those who were harmed.